Pasar al contenido principal

ESTUDIO DE LAS INTERACCIONES GENETICAS Y MECANISTICAS EN LA MIOCARDIOPATIA FAMILIAR MEDIANTE MODELAJE AVANZADO DE LA ENFERMEDAD

SAF2015-71863-REDT

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Redes Investigación /Redes Excelencia
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5

  • Domínguez, Fernando
  • Lalaguna, Laura
  • López-Olañeta, Marina
  • Padrón-Barthe, Laura
  • Román, Marta
  • Bello-Arroyo, Elísabet
  • Briceño, Ana
  • Gonzalez-Lopez, Esther
  • Segovia-Cubero, Javier
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
  • Villalba Orero, María
Background: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is an inherited cardiac disease with complete penetrance and an aggressive clinical course caused by mutations in TMEM43 (transmembrane protein 43). There is no cure for ARVC5 and palliative treatment is started once the phenotype is present. A transgenic mouse model of ARVC5 expressing human TMEM43-S358L (TMEM43mut) recapitulates the human disease, enabling the exploration of preventive treatments. The aim of this study is to determine whether preventive treatment with heart failure drugs (β-blockers, ACE [angiotensin-converting enzyme] inhibitors, mineralocorticoid-receptor antagonists) improves the disease course of ARVC5 in TMEM43mut mice. Methods: TMEM43mut male/female mice were treated with metoprolol (β-blockers), enalapril (ACE inhibitor), spironolactone (mineralocorticoid-receptor antagonist), ACE inhibitor + mineralocorticoid-receptor antagonist, ACE inhibitor + mineralocorticoid-receptor antagonist + β-blockers or left untreated. Drugs were initiated at 3 weeks of age, before ARVC5 phenotype, and serial ECG and echocardiograms were performed. Results: TMEM43mut mice treated with enalapril showed a significantly increased median survival compared with untreated mice (26 versus 21 weeks; P=0.003). Enalapril-treated mice also exhibited increased left ventricular ejection fraction at 4 months compared with controls (37.0% versus 24.9%; P=0.004), shorter QRS duration and reduced left ventricle fibrosis. Combined regimens including enalapril also showed positive effects. Metoprolol decreased QRS voltage prematurely and resulted in a nonsignificant decrease in left ventricular ejection fraction compared with untreated TMEM43mut mice. Conclusions: Preventive enalapril-based regimens reduced fibrosis, improved ECG, echocardiographic parameters and survival of ARVC5 mice. Early metoprolol did not show positive effects and caused premature ECG abnormalities. Our findings pave the way to consider prophylactic enalapril in asymptomatic ARVC5 genetic carriers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic etiology for alcohol-induced cardiac toxicity

  • Ware, James S.
  • Amor-Salamanca, Almudena|||0000-0003-0420-8207
  • Tayal, Upasana
  • Govind, Risha
  • Serrano, Isabel
  • Salazar-Mendiguchía, Joel|||0000-0003-2171-8508
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Pascual-Figal, DA.|||0000-0002-4993-9540
  • Núñez, Julio|||0000-0003-1672-7119
  • Guzzo-Merello, Gonzalo
  • González-Vioque, Emiliano
  • Bardají, Alfredo|||0000-0003-1900-6974
  • Manito, Nicolas
  • López-Garrido, Miguel A.
  • Padron-Barthe, Laura
  • Edwards, Elizabeth
  • Whiffin, Nicola
  • Walsh, Roddy
  • Buchan, Rachel J.
  • Midwinter, William
  • Wilk, Alicja
  • Prasad, Sanjay
  • Pantazis, Antonis
  • Baski, John
  • O'Regan, Declan P.
  • Alonso-Pulpón, Luis
  • Cook, Stuart A.
  • Lara-Pezzi, Enrique
  • Barton, Paul J.
  • García-Pavía, Pablo|||0000-0002-5470-2257
Alcoholic cardiomyopathy (ACM) is defined by a dilated and impaired left ventricle due to chronic excess alcohol consumption. It is largely unknown which factors determine cardiac toxicity on exposure to alcohol. This study sought to evaluate the role of variation in cardiomyopathy-associated genes in the pathophysiology of ACM, and to examine the effects of alcohol intake and genotype on dilated cardiomyopathy (DCM) severity. The authors characterized 141 ACM cases, 716 DCM cases, and 445 healthy volunteers. The authors compared the prevalence of rare, protein-altering variants in 9 genes associated with inherited DCM. They evaluated the effect of genotype and alcohol consumption on phenotype in DCM. Variants in well-characterized DCM-causing genes were more prevalent in patients with ACM than control subjects (13.5% vs. 2.9%; p = 1.2 ×10 ⁻⁵), but similar between patients with ACM and DCM (19.4%; p = 0.12) and with a predominant burden of titin truncating variants (TTNtv) (9.9%). Separately, we identified an interaction between TTN genotype and excess alcohol consumption in a cohort of DCM patients not meeting ACM criteria. On multivariate analysis, DCM patients with a TTNtv who consumed excess alcohol had an 8.7% absolute reduction in ejection fraction (95% confidence interval: -2.3% to -15.1%; p < 0.007) compared with those without TTNtv and excess alcohol consumption. The presence of TTNtv did not predict phenotype, outcome, or functional recovery on treatment in ACM patients. TTNtv represent a prevalent genetic predisposition for ACM, and are also associated with a worse left ventricular ejection fraction in DCM patients who consume alcohol above recommended levels. Familial evaluation and genetic testing should be considered in patients presenting with ACM.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pot1 and damage response malfunction trigger acquisition of somatic activating mutations in the vegf pathway in cardiac angiosarcomas

  • Calvete, Oriol|||0000-0002-2623-2876
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Domınguez, Fernando|||0000-0001-8408-363X
  • Mosteiro, Lluc|||0000-0003-4041-9706
  • Perez Cabornero, Lucía|||0000-0002-2605-9006
  • Cantalapiedra, Diego
  • Zorio, Esther|||0000-0003-3608-4210
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Teule, Alex|||0000-0003-0028-7200
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Morente, Manuel M.|||0000-0001-6004-330X
  • Urioste, Miguel|||0000-0001-7583-7305
  • Benitez, Javier|||0000-0002-0923-7202
Mutations in the POT1 gene explain abnormally long telomeres and multiple tumors including cardiac angiosarcomas (CAS). However, the link between long telomeres and tumorigenesis is poorly understood. Here, we have studied the somatic landscape of 3 different angiosarcoma patients with mutations in the POT1 gene to further investigate this tumorigenesis process. In addition, the genetic landscape of 7 CAS patients without mutations in the POT1 gene has been studied. Patients with CAS and nonfunctional POT1 did not repress ATR (ataxia telangiectasia RAD3-related)-dependent DNA damage signaling and showed a constitutive increase of cell cycle arrest and somatic activating mutations in the VEGF (vascular endothelial growth factor)/angiogenesis pathway (KDR gene). The same observation was made in POT1 mutation carriers with tumors different from CAS and also in CAS patients without mutations in the POT1 gene but with mutations in other genes involved in DNA damage signaling. Inhibition of POT1 function and damage-response malfunction activated DNA damage signaling and increased cell cycle arrest as well as interfered with apoptosis, which would permit acquisition of somatic mutations in the VEGF/angiogenesis pathway that drives tumor formation. Therapies based on the inhibition of damage signaling in asymptomatic carriers may diminish defects on cell cycle arrest and thus prevent the apoptosis deregulation that leads to the acquisition of driver mutations.